WO2010010133A1 - Phénylacétamides à substitution 2-thia-1,3-diazaspirocyclique utilisés comme médiateurs glt1 dans les maladies neurologiques - Google Patents

Phénylacétamides à substitution 2-thia-1,3-diazaspirocyclique utilisés comme médiateurs glt1 dans les maladies neurologiques Download PDF

Info

Publication number
WO2010010133A1
WO2010010133A1 PCT/EP2009/059456 EP2009059456W WO2010010133A1 WO 2010010133 A1 WO2010010133 A1 WO 2010010133A1 EP 2009059456 W EP2009059456 W EP 2009059456W WO 2010010133 A1 WO2010010133 A1 WO 2010010133A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
hydrogen
compound
halo
Prior art date
Application number
PCT/EP2009/059456
Other languages
English (en)
Inventor
Kevin Dinnell
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of WO2010010133A1 publication Critical patent/WO2010010133A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to sultam compounds, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GIyTI , including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.
  • GIyTI is found predominantly in the forebrain and its distribution corresponds to that of glutaminergic pathways and NMDA receptors (Smith, et al., Neuron, 8, 1992: 927-935).
  • GIyT-Ia three variants of GIyTI , termed GIyT-Ia, GIyT-I b and GIyT-I c (Kim et al., Molecular Pharmacology, 45, 1994: 608-617), each of which displays a unique distribution in the brain and peripheral tissues.
  • GlyT2 in contrast, is found predominantly in the brain stem and spinal cord, and its distribution corresponds closely to that of strychnine-sensitive glycine receptors (Liu et al., J. Biological Chemistry, 268, 1993: 22802-22808; Jursky and Nelson, J. Neurochemistry, 64, 1995 : 1026-1033).
  • GlyT2 Another distinguishing feature of glycine transport mediated by GlyT2 is that it is not inhibited by sarcosine as is the case for glycine transport mediated by GIyTL
  • NMDA receptors are critically involved in memory and learning (Rison and Staunton, Neurosci. Biobehav. Rev., 19 533-552 (1995); Danysz et al, Behavioral Pharmacol., 6 455-474 (1995)); and, furthermore, decreased function of NMDA-mediated neurotransmission appears to underlie, or contribute to, the symptoms of schizophrenia (Olney and Farber, Archives General Psychiatry, 52, 998-1007 (1996).
  • agents that inhibit GIyTI and thereby increase glycine activation of NMDA receptors can be used as novel antipsychotics and anti-dementia agents, and to treat other diseases in which cognitive processes are impaired, such as attention deficit disorders and organic brain syndromes.
  • NMDA receptors have been implicated in a number of disease states, in particular the neuronal death associated with stroke and possibly neurodegenerative diseases, such as Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or other conditions in which neuronal cell death occurs, such as stroke or head trauma.
  • neurodegenerative diseases such as Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or other conditions in which neuronal cell death occurs, such as stroke or head trauma.
  • Coyle & Puttfarcken Science, 262, 689-695 (1993); Lipton and Rosenberg, New Engl. J. of Medicine. 330. 613-622 (1993); Choi, Neuron. 1 , 623-634 (1988).
  • pharmacological agents that increase the activity of GIyTI will result in decreased glycine- activation of NMDA receptors, which activity can be used to treat these and related disease states.
  • drugs that directly block the glycine site of the NMDA receptors can be used to treat these and related disease states.
  • Glycine transport inhibitors are already known in the art, for example as disclosed in published international patent application WO03/055478 (SmithKline Beecham).
  • R 1 , R 2 , R 3 and R 4 are each independently selected from hydrogen, C 1-4 alkyl, C 1- 4 alkoxy, cyano, halo, haloCi -4 alkyl, haloCi -4 alkoxy, Ci -4 alkylthio, C 3-6 cycloalkyl, C 3 - 6 cycloalkylC 2 - 4 alkyl, C ⁇ alkylsulfonyl, Ci -4 alkoxyCi -4 alkyl and C(O)NR a R b (wherein R a and R b are independently selected from hydrogen and C 1-4 alkyl, or R a and R b , together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring);
  • R 2 and R 3 together form a group selected from -0-CH 2 -O- and -0-CH 2 -CH 2 -O-;
  • R 5 is selected from hydrogen, chloro, fluoro, Ci- 4 alkyl and CF 3 ;
  • R 6 and R 7 is selected from hydrogen, Ci -4 alkyl, Ci -4 alkoxy, haloCi -4 alkyl, haloC 1-4 alkoxy, halo, cyano, C 1-4 alkoxyC 1-4 alkoxy, C 1-4 alkoxyC 1-4 alkyl, C 1-4 alkylsulfonyl,
  • Ci -4 alkylthio COR 9 (wherein R 9 is hydrogen or C 1-4 alkyl), CONR'R J (wherein R' and R J are independently selected from hydrogen, C- ⁇ alkyl or, together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), CHR k NR'R m (wherein R k is hydrogen or Ci -4 alkyl and R 1 and R m are independently selected from hydrogen and Ci -4 alkyl, or R 1 and R m , together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), a 5 to 7 membered heteroaryl ring (optionally substituted by C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkyl, haloC 1-4 alkoxy, halo or cyano), a 9 to 10 membered bicyclic heterocyclic ring (optionally substituted by Ci- 4 alkyl, Ci -4 alkoxy,
  • R 6 and R 7 is selected from the group consisting of hydrogen, d- 4alkyl, d- 4 alkoxy, haloCi- 4 alkyl, halod- 4 alkoxy, halo, cyano, d- 4 alkoxyd- 4 alkoxy and Ci -4 alkoxyCi -4 alkyl; • or R 6 and R 7 together form a 5 to 7 membered heterocyclic ring fused to the phenyl ring or a 5 to 7 membered heteroaryl ring fused to the phenyl ring, wherein the heterocyclic ring or the heteroaryl ring is optionally substituted by haloCi_ 4 alkyl, haloCi -4 alkoxy, halo or cyano;
  • n is selected from 1 and 2.
  • C 1-4 alkyl refers to a straight or branched alkyl group of 1-4 carbon atoms in all isomeric forms. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
  • C 1-4 alkoxy refers to the group -O-Ci -4 alkyl wherein Ci -4 alkyl is as defined above.
  • C 1-4 alkoxyCi -4 alkyl refers to the group -(Ci -4 alkyl)-O-(Ci -4 alkyl), wherein C 1-4 alkyl is as defined above.
  • Ci -4 alkoxyCi -4 alkyoxy refers to the group -O-(Ci -4 alkyl)-O-(Ci_ 4 alkyl), wherein C 1-4 alkyl is as defined above.
  • d- ⁇ cycloalkyr refers to a cycloalkyl group consisting of from 3 to 6 carbon atoms, ie cyclopropane, cyclobutane, cyclopentane or cyclohexane.
  • halogen and its abbreviation "halo” refer to fluorine, chlorine, bromine, or iodine.
  • Preferred halo substituents in compounds of the invention are fluorine, chlorine and bromine atoms.
  • haloC 1-4 alkyl refers to a C 1-4 alkyl group as defined above which is substituted with any number of fluorine, chlorine, bromine, or iodine atoms, including with mixtures of those atoms.
  • a group may, for example contain 1 , 2 or 3 halogen atoms.
  • a haloC 1-4 alkyl group may have all hydrogen atoms replaced with halogen atoms.
  • haloCi -4 alkyl groups include fluoromethyl, difluoromethyl and trifluoromethyl.
  • haloCi -4 alkoxy refers to a group as defined above which is substituted with any number of fluorine, chlorine, bromine, or iodine atoms, including with mixtures of those atoms.
  • a haloC 1-4 alkoxy group may, for example contain 1 , 2 or 3 halogen atoms.
  • a haloCi -4 alkoxy group may have all hydrogen atoms replaced with halogen atoms. Examples of groups include fluoromethyloxy, difluoromethyloxy and trifluoromethyloxy.
  • cyano refers to a group -CN.
  • C 1-4 alkylsulfonyl refers to a group -S(O) 2 -(Ci -4 alkyl).
  • An example is -S(O) 2 CH 3 .
  • C 1-4 alkylthio refers to a group -S-(Ci -4 alkyl).
  • An example is -SCH 3 .
  • R a and R b together with the nitrogen atom to which they are attached, may form a saturated 4- to 7-membered ring, ie an azetidinyl, pyrrolidinyl, piperidyl, or azepanyl group.
  • R 1 is selected from hydrogen, Ci -2 alkyl, Ci -2 alkoxy, halo, haloC 1-2 alkyl, haloC 1-2 alkoxy, C 1-2 alkylthio, C 1-2 alkylsulfonyl, C 1-2 alkoxyC 1-2 alkyl and cyano.
  • R 1 is hydrogen
  • R 2 is selected from hydrogen, Ci -2 alkyl, Ci -2 alkoxy, halo, haloCi_ 2 alkyl, haloCi -2 alkoxy, Ci -2 alkylthio, Ci -2 alkylsulfonyl, Ci -2 alkoxyCi -2 alkyl and cyano.
  • R 2 is halo. In one embodiment, R 2 is fluoro. In one embodiment, R 2 is haloCi_ 4 alkyl. In one embodiment, R 2 is haloCi -2 alkyl. In one embodiment, R 2 is CF 3 .
  • R 3 is selected from hydrogen, Ci -2 alkyl, Ci -2 alkoxy, halo, haloCi_ 2 alkyl, haloCi -2 alkoxy, Ci -2 alkylthio, Ci -2 alkylsulfonyl, Ci -2 alkoxyCi -2 alkyl and cyano. In a further embodiment, R 3 is hydrogen.
  • R 4 is selected from hydrogen, Ci -2 alkyl, Ci -2 alkoxy, halo, haloC 1-2 alkyl, haloC 1-2 alkoxy, C 1-2 alkylthio, C 1-2 alkylsulfonyl, C 1-2 alkoxyC 1-2 alkyl and cyano. In a further embodiment, R 4 is halo. In a further embodiment, R 4 is fluoro. In one embodiment, R 4 is hydrogen.
  • R 5 is hydrogen
  • R 1 is hydrogen
  • R 2 is halo or haloCi -4 alkyl
  • R 3 is hydrogen
  • R 4 is halo or hydrogen
  • R 5 is hydrogen
  • R 6 is selected from halo, Ci -4 alkoxyCi -4 alkyl, Ci- 4 alkylthio, COR 9 and a 5 to 7 membered heteroaryl ring (optionally substituted by
  • R 6 is selected from halo, Ci -2 alkoxyCi -2 alkyl, Ci -2 alkylsulfonyl, Ci -2 alkylthio, COR 9 and 5 to
  • R 6 is selected from -Br, -COH, - SO 2 CH 3 , -SCH 3 , -CH(CH 3 )OCH 3 , -CH 2 CH 2 OCH 3 , -CH 2 OCH 3 and 4-methyl-1-imidazolyl.
  • R 6 is selected from halo, C 1-2 alkoxyC 1-2 alkyl and 5 to 7 membered heteroaryl ring (optionally substituted by Ci -4 alkyl).
  • R 6 is C 1-2 alkoxyC 1-2 alkyl. In a further embodiment, R 6 is selected from -CH(CH 3 )OCH 3 , -CH 2 CH 2 OCH 3 and -CH 2 OCH 3 . In one embodiment, R 6 is selected from - CH(CH 3 )OCH 3 and -CH 2 OCH 3 .
  • R 6 is halo. In one embodiment, R 6 is bromo.
  • R 6 is a 5 to 7 membered heteroaryl ring, which is optionally substituted by Ci -4 alkyl, Ci -4 alkoxy, haloCi -4 alkyl, halo or cyano.
  • R 6 is a 5 to 7 membered heteroaryl ring, which is optionally substituted by C 1-4 alkyl.
  • R 6 is 4-methyl-1-imidazolyl.
  • R 7 is selected from hydrogen, Ci -2 alkyl, Ci -2 alkoxy, haloCi -2 alkyl, haloC 1-2 alkoxy, halo, cyano, C 1-2 alkoxyC 1-2 alkoxy and C 1-2 alkoxyC 1-2 alkyl. In a further embodiment, R 7 is hydrogen.
  • R 6 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkyl, haloCi_ 4 alkoxy, halo, cyano, Ci -4 alkoxyCi -4 alkoxy and and R 7 is selected from a 5 to 7 membered heteroaryl ring (optionally substituted by C 1-4 alkoxy, haloC 1-4 alkyl, haloC 1-4 alkoxy, halo or cyano), a 9 to 10 membered bicyclic heterocyclic ring (optionally substituted by Ci -4 alkoxy, haloCi -4 alkyl, haloCi_ 4 alkoxy, halo or cyano) and a 5 to 7 membered heterocyclic ring (optionally substituted by C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkyl, haloC 1-4 alkoxy, halo or cyano).
  • R 7 is selected from the group consisting of hydrogen, Ci- 4 alkyl, C ⁇ alkoxy, haloC ⁇ alkyl, haloC ⁇ alkoxy, halo, cyano, C ⁇ alkoxyC ⁇ alkoxy and Ci -4 alkoxyCi.
  • R 6 is selected from hydrogen, Ci -4 alkyl, Ci -4 alkoxy, haloCi -4 alkoxy, halo, cyano, Ci -4 alkylsulfonyl, C 1-4 alkylthio, COR 9 (wherein R 9 is hydrogen or C 1-4 alkyl), CONR'R J (wherein R' and R J are independently selected from hydrogen, Ci -4 alkyl or, together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), CHR k NR'R m (wherein R k is hydrogen or C 1-4 alkyl and R 1 and R m are independently selected from hydrogen and Ci -4 alkyl or R 1 and R m , together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), a 5 to 7 membered heteroaryl ring (optionally substituted by C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4
  • R 7 is selected from hydrogen, Ci -4 alkyl, Ci -4 alkoxy, haloCi -4 alkyl, haloC 1-4 alkoxy, halo, cyano, C 1-4 alkoxyC 1-4 alkoxy and C 1-4 alkoxyC 1-4 alkyl; and R 6 is selected from Ci -4 alkylthio, COR 9 (wherein R 9 is hydrogen or Ci -4 alkyl), CONR'R J (wherein R' and R J are independently selected from hydrogen, C- ⁇ alkyl or, together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), CHR k NR'R m (wherein R k is hydrogen or C 1-4 alkyl and R 1 and R m are independently selected from hydrogen and or R 1 and R m , together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), a 5 to 7 membered heteroaryl ring (optionally substitute
  • R 7 is selected from hydrogen, Ci -4 alkyl, Ci -4 alkoxy, haloCi -4 alkyl, haloCi -4 alkoxy, halo, cyano
  • R 6 is selected from a 5 to 7 membered heteroaryl ring (optionally substituted by C 1-4 alkyl, C 1- 4 alkoxy, haloCi -4 alkyl, haloCi -4 alkoxy, halo or cyano), a 9 to 10 membered bicyclic heterocyclic ring (optionally substituted by Ci -4 alkyl, haloCi -4 alkyl, haloCi.
  • R 7 is hydrogen; and R 6 is selected from hydrogen, C 1-4 alkyl, Ci -4 alkoxy, haloCi -4 alkyl, haloCi -4 alkoxy, halo, cyano, Ci- 4 alkoxyCi- 4 alkyl, Ci -4 alkylsulfonyl, Ci -4 alkylthio, COR 9 (wherein R 9 is hydrogen or C 1-4 alkyl), CONR'R J (wherein R' and R J are independently selected from hydrogen, Ci -4 alkyl or, together with the nitrogen atom to which they are attached, form a 4, 5 or 6- membered ring), CHR k NR'R m (wherein R k is hydrogen or C- ⁇ alkyl and R 1 and R m are independently selected from hydrogen and C 1-4 alkyl or R 1 and R m , together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), a 5 to 7 membered heteroaryl
  • R 6 is selected from halo, Ci -2 alkoxyCi -2 alkyl and 5 to 7 membered heteroaryl ring (optionally substituted by C 1-4 alkyl); and R 7 is selected from hydrogen, Ci -2 alkyl, Ci -2 alkoxy, haloCi -2 alkyl, haloCi -2 alkoxy, halo, cyano, Ci -2 alkoxyCi -2 alkoxy and Ci -2 alkoxyCi -2 alkyl.
  • R 6 is is selected from halo, C 1-2 alkoxyC 1-2 alkyl and 5 to 7 membered heteroaryl ring (optionally substituted by Ci -4 alkyl); and R 7 is hydrogen.
  • R 8 is hydrogen
  • R 15 is hydrogen
  • n is 1. In one embodiment, m is 0.
  • n is 2.
  • X is -CH 2 - or oxygen
  • R 1 , R 2 , R 3 and R 4 are each independently selected from hydrogen, cyano, halo, haloCrCUalkyl, haloCrCUalkoxy, CrCUalkylthio, C 3 -C 6 cycloalkyl, Ci-C 4 alkylsulfonyl, Ci- 4 alkoxyC r4 alkyl and CONR a R b (wherein R a and R b are independently selected from hydrogen and CrC 4 alkyl, or R a and R b , together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring); or R 2 and R 3 together form a group selected from -0-CH 2 -O- and -0-CH 2 -CH 2 -O-; R 5 is selected from hydrogen, chloro, fluoro, Ci-C 4 alkyl and CF 3 ; R 6 is selected from halo, C- M alkoxyC- M alkyl and a 5 to 7 member
  • R 7 is selected from hydrogen, Ci-C 4 alkyl, C 1 -C 4 BIkOXy, haloC 1 -C 4 alkyl, haloC 1 -C 4 alkoxy, halo, cyano, Ci-C 4 alkoxyCi-C 4 alkoxy and R 8 is selected from hydrogen and methyl; R 15 is selected from hydrogen and fluroine; m is selected from 0, 1 and 2; and n is selected from 1 or 2.
  • R 2 is selected from hydrogen, halo, haloCi -4 alkyl, haloCi -4 alkoxy, C 1-4 alkylthio, C 3-6 cycloalkyl, C 1-4 alkylsulfonyl, C 1-4 alkoxyC 1-4 alkyl, cyano and CONR c R d (wherein R c and R d are independently selected from H and C 1-4 alkyl, or R c and R d , together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring);
  • R 4 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, halo, haloC 1-4 alkyl, haloC 1-4 alkoxy, Ci -4 alkylthio, C 3-6 cycloalkyl, Ci -4 alkylsulfonyl, cyano and CONR 9 R h (wherein R 9 and R h are independently selected from hydrogen and C 1-4 alkyl, or R 9 and R h , together with the nitrogen atom to which they are attached, form a 4- to 7- membered ring);
  • R 6 is selected from halo, C 1-4 alkoxyC 1-4 alkyl and a 5 to 7 membered heteroaryl ring (optionally substituted by C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkyl, haloC 1-4 alkoxy, halo or cyano);
  • R ->2 is selected from halo and haloCi -4 alkyl
  • R 4 is selected from hydrogen and halo
  • R 6 is selected from halo, and a 5 to 7 membered heteroaryl ring
  • n is selected from 1 and 2.
  • any one feature of the compounds of the invention may be combined with any embodiment of another feature of compounds of the invention to create a further embodiment.
  • Examples of compounds of the invention include:
  • Salts of compounds of formula (I) which are suitable for use in medicine are those wherein the counterion is pharmaceutically acceptable.
  • salts having non- pharmaceutically acceptable counterions are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formula (I) and their pharmaceutically acceptable salts.
  • the term "salt” refers to any salt of a compound according to the present invention prepared from an inorganic or organic acid or base, quaternary ammonium salts and internally formed salts.
  • Pharmaceutically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compounds. Such salts must clearly have a pharmaceutically acceptable anion or cation.
  • Suitably pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, (1 R)-(-)-10-camphorsulphonic, (1 S)-(+)-10- camphorsulphonic, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alg
  • Salts having a non-pharmaceutically acceptable anion or cation are within the scope of the invention as useful intermediates for the preparation of pharmaceutically acceptable salts and/or for use in non-therapeutic, for example, in vitro, situations.
  • the salts may have any suitable stoichiometry.
  • a salt may have 1 :1 or 2:1 stoichiometry.
  • Non-integral stoichiometry ratios are also possible.
  • Solvates of the compounds of formula (I) and solvates of the salts of the compounds of formula (I) are included within the scope of the present invention.
  • the term "solvate” refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent.
  • solute in this invention, a compound of formula (I) or a salt thereof
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include, without limitation, water, ethanol and acetic acid.
  • the solvent used is water. Where the solvent used is water such a solvate may then also be referred to as a hydrate.
  • compounds of formula (I) (whether in solvated or unsolvated form) or their pharmaceutically acceptable salts (whether in solvated or unsolvated form) or prodrugs thereof defined in any aspect of the invention (except intermediate compounds in chemical processes) are referred to as "compounds of the invention".
  • the compounds of formula (I) may have the ability to crystallise in more than one form. This is a characteristic known as polymorphism, and it is understood that such polymorphic forms (“polymorphs”) are within the scope of formula (I). Polymorphism generally can occur as a response to changes in temperature or pressure or both and can also result from variations in the crystallisation process. Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility, and melting point.
  • Stereoisomers may be separated by high- performance liquid chromatography or other appropriate means.
  • a compound When a compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art.
  • an optically pure enantiomer of a compound of the present invention is provided.
  • optically pure enantiomer means that the compound contains greater than about 90 % of the desired isomer by weight, such as greater than about 95 % of the desired isomer by weight, or greater than about 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound.
  • Prodrugs may be placed on appropriate functionalities when such functionalities are present within compounds of the invention.
  • Examples of prodrugs for certain compounds of the invention include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.
  • the invention also includes all suitable isotopic variations of a compound of the invention.
  • An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F and 36 CI, respectively.
  • isotopic variations of the invention are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances.
  • Isotopic variations of the compounds of the invention can generally be prepared by conventional procedures such as by the illustrative methods or by the preparations described in the Examples hereafter using appropriate isotopic variations of suitable reagents.
  • Compounds of formula (I) can be prepared by reacting a compound of formula (II) with a compound of formula (III) in the presence of a base, for example potassium carbonate, in a suitable inert solvent, for example acetone, optionally in the presence of an iodide source such as tetrabutylammonium iodide, at ambient or elevated temperature as shown in Scheme 1 , where L is a leaving group such as chloro or bromo.
  • a base for example potassium carbonate
  • a suitable inert solvent for example acetone
  • an iodide source such as tetrabutylammonium iodide
  • Compounds of formula (Na) where n is 2 may be prepared by reaction of compounds of formula (Vl) with a reagent such as sulphuryl chloride, chlorosulphonic acid or sulphamide in the presence of a base such as pyridine or triethylamine, optionally in an inert solvent such as dichloromethane or tetrahydrofuran, at reduced, ambient or elevated temperature as shown in Scheme 3. Alternatively use of excess base can act as the solvent.
  • a reagent such as sulphuryl chloride, chlorosulphonic acid or sulphamide
  • a base such as pyridine or triethylamine
  • an inert solvent such as dichloromethane or tetrahydrofuran
  • Compounds of formula (lib) where n is 1 may be prepared by reaction of compounds of formula (V) with a reagent such as thionyl chloride in the presence of a base such as pyridine or triethylamine, optionally in an inert solvent such as dichloromethane or tetrahydrofuran at reduced, ambient or elevated temperature as shown in scheme 4. Use of excess base can also act as the solvent.
  • a reagent such as thionyl chloride in the presence of a base such as pyridine or triethylamine, optionally in an inert solvent such as dichloromethane or tetrahydrofuran at reduced, ambient or elevated temperature as shown in scheme 4.
  • Diamines of formula (Vl) can be prepared, for example, in two steps from amino acids of formula (VII) by firstly reaction with a aniline of formula (VIII) using a diimide reagent such as N, N dicyclohexylcarbodiimide (DCC), N-(3-(dimethylamino)propyl)-N-ethylcarbodiimide hydrochloride (EDC) or O-(7-azabenzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluoro phosphate (HATU) in an inert solvent such as dichloromethane or N,N-dimethylformamide at ambient or elevated temperature, followed by reduction of amide (IX) to a compound of formula (Vl) by reaction with an agent such as lithium aluminium hydride or borane in a suitable solvent such as tetrahydrofuran at ambient, or preferably elevated, temperature as in Scheme 5.
  • a compound of structure (Xl) for example, treatment of a compound of structure (Xl) with an appropriate palladium catalyst such as tetrakis(triphenylphosphine)palladium[0] or palladium acetate in conjunction with a phosphine ligand such as 1 ,3-(bis)triphenylphosphino)propane, a base such as sodium carbonate, triethylamine or diisopropylamine and a heteroaryl boronic acid or heteroaryl trialkyltin reagent may undergo palladium mediated coupling to give a compound of formula (II) where R 6 is a carbon linked heteroaryl group
  • These reactions may be performed in a range of solvents including tetrahydrofuran, dimethylformamide, dioxan or toluene, or combinations of solvents, optionally in the presence of an ionic liquid such as 1-butyl-3-imidazolium tetrafluoroborate either at
  • a compound of structure (Xl) with an appropriate palladium catalyst such as tetrakis(triphenylphosphine)palladium[0] or palladium acetate in conjunction with a phosphine ligand such as 2,2'-bis(diphenylphosphino)-1 ,1 '- binaphthalene (BINAP), a base such as cesium carbonate or potassium phosphate, and a 5 to 7 membered heterocyclic ring containing a secondary amine, such as piperidine or morpholine, may undergo palladium mediated coupling to give a compound of formula (II) where R 6 is a nitrogen linked 5-7 membered heterocyclic group.
  • an appropriate palladium catalyst such as tetrakis(triphenylphosphine)palladium[0] or palladium acetate
  • a phosphine ligand such as 2,2'-bis(diphenylphosphino)-1 ,1 '
  • reaction may be performed in a range of solvents including tetrahydrofuran, dimethylformamide, dioxan or toluene, or combinations of solvents, optionally in the presence of an ionic liquid such as 1-butyl-3-imidazolium tetrafluoroborate either at ambient or preferably elevated temperatures.
  • solvents including tetrahydrofuran, dimethylformamide, dioxan or toluene, or combinations of solvents, optionally in the presence of an ionic liquid such as 1-butyl-3-imidazolium tetrafluoroborate either at ambient or preferably elevated temperatures.
  • a compound of structure (Xl) with an appropriate copper catalyst such as copper (I) bromide or copper (I) iodide, in conjunction with a ⁇ -ketoester ligand such as ethyl 2-oxocyclohexanecarboxylate or diamine ligand such as trans-1 ,2- diaminocylohexane, a base such as cesium carbonate or potassium phosphate and a heteroaryl or 2-oxo substituted 5-7 membered heterocyclic ring containing a free NH, may undergo copper mediated coupling to give a compound of formula (II) where R 6 is a nitrogen linked heteroaromatic or 2-oxo substituted 5-7 membered heterocyclic ring.
  • an appropriate copper catalyst such as copper (I) bromide or copper (I) iodide
  • a ⁇ -ketoester ligand such as ethyl 2-oxocyclohexanecarboxylate or diamine ligand such
  • reaction may be performed in a range of solvents such as dimethyl sulphoxide, N,N-dimethylformamide, N-methylpyrrolidinone, acetonitrile or dioxan or combinations of solvents, optionally in the presence of an ionic liquid such as 1-butyl-3-imidazolium tetrafluoroborate either at ambient or preferably elevated temperatures.
  • solvents such as dimethyl sulphoxide, N,N-dimethylformamide, N-methylpyrrolidinone, acetonitrile or dioxan or combinations of solvents
  • compounds of formula (II) wherein R 7 , R 8 and R 21 , X, m and n are as defined in formula (I) and R 6 is a carbon linked heteroaryl group can be prepared as shown in scheme 8 through intermediates such as where R 6 is a carboxylic acid (XII) or R 6 is a cyano group (XIII) using standard methods for preparation of heterocyclic systems such as those described in series such as Organic Syntheses, The Chemistry of Heterocycles or Comprehensive Heterocyclic Chemistry.
  • Nitrile (XIII) may be prepared from (Xl) by treatment with a cyanide source such as copper (I) cyanide, in a solvent such as N,N-dimethylformamide or N-methylpyrrolidinone at elevated temperature.
  • Carboxylic acid (XII) may be prepared by acidic hydrolysis of nitrile (XIII) or directly from (Xl) by treatment with 2 equivalents of alkyllithium at reduced temperature followed by addition of carbon dioxide, or through palladium mediated carbonylation methodology.
  • R 1 , R 2 , R 3 , R 4 , R 5 R 6 R 7 , R 8 , R 15 , X, m and n are as defined for compounds of formula (I).
  • Compounds of formula (XIV) can be prepared using standard methods from compounds of formula (II), step (iii), for example, by reaction with an appropriate haloester in the presence of a base, such as sodium hydride or potassium carbonate, in a suitable inert solvent, such as dimethylformamide, at room temperature or elevated temperature as appropriate.
  • a base such as sodium hydride or potassium carbonate
  • a suitable inert solvent such as dimethylformamide
  • Step (iv) Removal of the ester group R from compounds of formula (XIV) to afford the acids of formula (XV), step (iv), can be achieved by known methods, for example by use of a base, such as sodium hydroxide, in an inert solvent, such as aqueous methanol or aqueous ethanol, with or without heating as appropriate.
  • a base such as sodium hydroxide
  • an inert solvent such as aqueous methanol or aqueous ethanol
  • acylation step (v) can be achieved by reaction of the acid (XV) with an aniline of formula (IV), in an inert solvent, such as dichloromethane in the presence of a coupling reagent, for example a diimide reagent such as N, N dicyclohexylcarbodiimide (DCC), N-(3-(dimethylamino)propyl)-N-ethylcarbodiimide hydrochloride (EDC), or O-(7- azabenzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluoro phosphate (HATU).
  • a coupling reagent for example a diimide reagent such as N, N dicyclohexylcarbodiimide (DCC), N-(3-(dimethylamino)propyl)-N-ethylcarbodiimide hydrochloride (EDC), or O-(7-
  • R 6 R 7 , R 8 , R 21 , X, m and n are as defined in formula (I) and L represents a suitable leaving group.
  • leaving groups include halogen, OC(O)-alkyl, OC(O)- O-alkyl and OS(O) 2 Me.
  • L may be halogen and acylation in step (vi) may be carried out in an inert solvent such as dichloromethane, in the presence of a base, such as triethylamine.
  • a compound of formula (I) where R 6 is bromo may be converted to compounds of formula (I) wherein R 6 is heteroaryl or a 5-7 membered heterocyclic ring using either palladium or copper mediated coupling using methods as indicated in Scheme 7.
  • a heterocycle may be constructed from a compound of formula (I) where R 6 is bromo via a carboxylic acid or cyano intermediate using procedures as indicated in Scheme 8.
  • a compound of formula (I), or a suitable intermediate, where n is 1 can be converted to the corresponding compound where n is 2 by oxidation with a reagent such as 3-chloroperoxybenzoic acid in an inert solvent such as dichloromethane or chloroform at reduced, ambient or elevated temperature.
  • a reagent such as 3-chloroperoxybenzoic acid in an inert solvent such as dichloromethane or chloroform at reduced, ambient or elevated temperature.
  • Compounds of formula (I) can be converted into further compounds of formula (I) using alternative standard techniques. Salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • the present invention provides a process for the preparation of a compound of the invention, the process comprising:
  • R , R , R and R are as defined for formula (I), and L is a leaving group;
  • an activating agent such as methanesulphonyl chloride in presence of sutiable base and solvent, followed by treatment with a C 1-4 alkoxide in a suitable solvent, such as the corresponding Ci -4 alcohol; and thereafter optionally:
  • a suitable activating is methanesulphonyl chloride.
  • a suitable solvent is the corresponding Ci -4 alcohol.
  • X is -CH 2 - or oxygen; • one of R 6 and R 7 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkyl, haloC 1-4 alkoxy, halo, cyano, C 1-4 alkoxyC 1-4 alkoxy, C 1-4 alkoxyC 1-4 alkyl, C 1-4 alkylsulfonyl, Ci -4 alkylthio, COR 9 (wherein R 9 is hydrogen or Ci -4 alkyl), CONR'R J (wherein R' and R J are independently selected from hydrogen, C 1-4 alkyl or, together with the nitrogen atom to which they are attached, form a 4, 5 or 6-membered ring), CHR k NR'R m (wherein R k is hydrogen or Ci -4 alkyl and R 1 and R m are independently selected from hydrogen and C 1-4 alkyl or R 1 and R m , together with the nitrogen atom to which they are attached, form a 4,
  • R 6 and R 7 is selected from the group consisting of hydrogen, C 1-4 alkyl, Ci -4 alkoxy, haloCi -4 alkyl, haloCi -4 alkoxy, halo, cyano, and C 1-4 alkoxyC 1-4 alkyl;
  • R 6 and R 7 together form a 5 to 7 membered heterocyclic ring fused to the phenyl ring or a 5 to 7 membered heteroaryl ring fused to the phenyl ring, wherein the heterocyclic ring or the heteroaryl ring is optionally substituted by C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkyl, haloC 1-4 alkoxy, halo or cyano; • R 8 is selected from hydrogen and methyl;
  • R 15 is selected from hydrogen and fluorine
  • n is selected from 1 or 2.
  • a compound of formula (II) and salts thereof wherein X is -CH 2 -; R 6 is selected from hydrogen, Ci -4 alkyl, Ci -4 alkoxy, haloCi -4 alkyl, haloCi -4 alkoxy, halo, C 1-4 alkoxyC 1-4 alkoxy and C 1-4 alkoxyC 1-4 alkyl; R 7 is hydrogen; R 8 is selected from hydrogen and methyl; R 15 is hydrogen; m is 1 ; and n is selected from 1 or 2, and salts thereof.
  • the compounds of the present invention inhibit the GIyTI transporter, as measured by the assay below. Such compounds are therefore of potential utility for the treatment of certain neurological and neuropsychiatric disorders.
  • the compounds may selectively inhibit the GIyTI transporter over the GlyT2 transporter.
  • Some compounds of the invention may have mixed GIyTI /GlyT2 activity.
  • the affinities of the compounds of this invention for the GIyTI transporter can be determined by the following assay.
  • the compounds of the present invention were not necessarily from the same batch described below.
  • the test compound made in one batch may have been combined with other batch(es) for the assay.
  • HEK293 cells expressing the Glycine (Type 1 ) transporter are grown in cell culture medium [DMEM/NUT mix F12 containing 2mM L-Glutamine, 0.8mg/ml_ G418 and 10% heat inactivated fetal calf serum] at 37°C and 5% CO 2 .
  • Cells grown to 70-80% confluency in T175 flasks are harvested and resuspended at 4x10 5 cells/mL in assay buffer [14OmM NaCI, 5.4mM KCI, 1.8mM CaCI 2 , 0.8mM MgSO 4 , 2OmM HEPES, 5mM glucose and 5mM alanine, pH 7.4].
  • Compounds are considered to have activity at the the GIyTI transporter if they have a plC 50 of 5.0 or above.
  • Preferred compounds of the invention have a plC 50 of 5.6 or above and especially preferred coupunds of the invention have a plC 50 of 6.0 or above.
  • the example compound described below (Example 1 ) was found to have an average plC 50 at the GIyTI transporter of equal to or greater than 6.5.
  • Compounds that are considered to have selectively for inhibition of the GIyTI transporter over the GlyT2 transporter are those that have a greater activity at the GIyTI transporter than at the the GlyT2 transporter.
  • compounds may be considered to show selectivity for the GIyTI transporter if they have a plC 50 of 5.0 or above compared with a plC 50 of below 5.0 for the GlyT2 transporter.
  • Compounds considered to be particularly selective for inhibition of the GIyTI transporter over the GlyT2 transporter are those that have a plC 50 for the GIyTI transporter that is greater than the plC 50 for the GlyT2 transporter by 0.5 or more and compounds considered to be especially selective are those that have a plC 5 o for the GIyTI transporter that is greater than the plC 5 o for the GlyT2 transporter by 1.0 or more.
  • the example compound described below (Example 1 ) was found to have an average plC 50 at the GlyT2 transporter of less than 4.6.
  • disorders mediated by GIyTI refers to disorders that may be treated by the administration of a medicament that alters the activity of the GIyTI transporter.
  • disorders include neurological and neuropsychiatric disorders, including psychoses such as schizophrenia, dementia and other forms of impaired cognition such as attention deficit disorders and organic brain syndromes.
  • neuropsychiatric disorders include drug-induced (phencyclidine, ketamine and other dissociative anesthetics, amphetamine and other psychostimulants and cocaine) psychosis, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, and psychosis NOS, "schizophrenia-spectrum” disorders such as schizoid or schizotypal personality disorders, or illness associated with psychosis (such as major depression, manic depressive (bipolar) disorder, Alzheimer's disease and post-traumatic stress syndrome), and NMDA receptor-related disorders such as autism, depression, benign forgetfulness, childhood learning disorders and closed head injury.
  • Other disorders include Parkinson's disease, dyskinetic disorders, cognitive impairment, emesis, movement disorders, amnesia, circadian rhythm disorders, aggression and vertigo.
  • the disorder mediated by GIyTI to be treated by the use or method as hereinbefore described is a psychosis, including schizophrenia, dementia and attention deficit disorders.
  • the disorder is schizophrenia.
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • DSM-IV Diagnostic and Statistical Manual of Mental Disorders
  • ICD-10 International Classification of Diseases
  • the compounds of the invention be of use in the treatment of schizophrenia including the subtypes Paranoid Type (295.30), Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and Residual Type (295.60); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) including the subtypes Bipolar Type and Depressive Type; Delusional Disorder (297.1 ) including the subtypes Erotomanic Type, Grandiose Type, Jealous Type, Persecutory Type, Somatic Type, Mixed Type and Unspecified Type; Brief Psychotic Disorder (298.8); Shared Psychotic Disorder (297.3); Psychotic Disorder Due to a General Medical Condition including the subtypes With Delusions and With Hallucinations; Substance-Induced Psychotic Disorder including the subtypes With Delusions (293.81 ) and With Hallucinations (293.82); and Psychotic Disorder Not Otherwise Specified (298.9).
  • the compounds of the invention may be also of use in the treatment of mood disorders including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (311 ); Bipolar Disorders including Bipolar I Disorder, Bipolar Il Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89), Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80); Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive-like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood Disorder (including the subtypes With Depressive Features, With Manic Features and With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90).
  • the compounds of the invention may also be of use in the treatment of anxiety disorders including Panic Attack, Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, Blood-lnjection-lnjury Type, Situational Type and Other Type), Social Phobia (300.23), Obsessive-Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81 ), Acute Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder and Anxiety Disorder Not Otherwise Specified (300.00).
  • anxiety disorders including Panic Attack, Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, Blood-lnjection-lnjury Type, Situational Type and Other Type), Social Phobia (300.23), Obsess
  • the compounds of the invention may also be of use in the treatment of substance-related disorders including Substance Use Disorders such as Substance Dependence and Substance Abuse; Substance-Induced Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood Disorder, Substance-Induced Anxiety Disorder, Substance-Induced sexual Dysfunction, Substance-Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder (Flashbacks); Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81 ), Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol-Induced Persisting Amnestic Disorder, Alcohol-
  • the compounds of the invention may also be of use in the treatment of sleep disorders including primary sleep disorders such as Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44); Sleep Disorder Due to a General Medical Condition; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type.
  • the compounds of the invention may also be of use in the treatment of eating disorders such as Anorexia Nervosa (307.1 ) including the subtypes Restricting Type and Binge- Eating/Purging Type; Bulimia Nervosa (307.51 ) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50).
  • eating disorders such as Anorexia Nervosa (307.1 ) including the subtypes Restricting Type and Binge- Eating/Purging Type; Bulimia Nervosa (307.51 ) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50).
  • the compounds of the invention may also be of use in the treatment of Autistic Disorder (299.00); Attention-Deficit /Hyperactivity Disorder including the subtypes Attention-Deficit /Hyperactivity Disorder Combined Type (314.01 ), Attention-Deficit /Hyperactivity Disorder Predominantly Inattentive Type (314.00), Attention-Deficit /Hyperactivity Disorder Hyperactive-Impulse Type (314.01 ) and Attention-Deficit /Hyperactivity Disorder Not Otherwise Specified (314.9); Hyperkinetic Disorder; Disruptive Behaviour Disorders such as Conduct Disorder including the subtypes childhood-onset type (321.81 ), Adolescent- Onset Type (312.82) and Unspecified Onset (312.89), Oppositional Defiant Disorder (313.81 ) and Disruptive Behaviour Disorder Not Otherwise Specified; and Tic Disorders such as Tourette's Disorder (307.23).
  • Attention-Deficit /Hyperactivity Disorder including the subtypes Attention
  • the compounds of the invention may also be of use in the treatment of Personality Disorders including the subtypes Paranoid Personality Disorder (301.0), Schizoid Personality Disorder (301.20), Schizotypal Personality Disorder (301 ,22), Antisocial Personality Disorder (301.7), Borderline Personality Disorder (301 ,83), Histrionic Personality Disorder (301.50), Narcissistic Personality Disorder (301 ,81 ), Avoidant Personality Disorder (301.82), Dependent Personality Disorder (301.6), Obsessive- Compulsive Personality Disorder (301.4) and Personality Disorder Not Otherwise Specified (301.9).
  • Paranoid Personality Disorder (301.0
  • Schizoid Personality Disorder 301.20
  • Schizotypal Personality Disorder 301 ,22
  • Antisocial Personality Disorder (301.7
  • Borderline Personality Disorder 301 ,83
  • Histrionic Personality Disorder 301.50
  • Narcissistic Personality Disorder 301 ,81
  • Avoidant Personality Disorder (301.82)
  • Dependent Personality Disorder (301.6
  • the compounds of the invention may also be of use in the treatment of cognitive impairment.
  • cognitive impairment includes for example the treatment of impairment of cognitive functions including attention, orientation, learning disorders, memory (i.e. memory disorders, amnesia, amnesic disorders, transient global amnesia syndrome and age-associated memory impairment) and language function; cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, Aids-related dementia or other dementia states such as Multiinfarct dementia, alcoholic dementia, hypotiroidism-related dementia, and dementia associated to other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis; other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic agents, mild cognitive impairment, age related cognitive impairment, autism related cognitive impairment, Down's syndrome, cognitive deficit related to psychosis, and post- electrostatic impairment
  • the compounds of the present invention may also be of use for the treatment of cognition impairment which arises in association or as a result of other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment.
  • the compounds of the invention may also be of use in the treatment of sexual dysfunctions including sexual Desire Disorders such as Hypoactive Sexual Desire Disorder (302.71 ), and sexual Aversion Disorder (302.79); sexual arousal disorders such as Female sexual Arousal Disorder (302.72) and Male Erectile Disorder (302.72); orgasmic disorders such as Female Orgasmic Disorder (302.73), Male Orgasmic Disorder (302.74) and Premature Ejaculation (302.75); sexual pain disorder such as Dyspareunia (302.76) and Vaginismus (306.51 ); sexual Dysfunction Not Otherwise Specified (302.70); paraphilias such as Exhibitionism (302.4), Fetishism (302.81 ), Frotteurism (302.89), Pedophilia (302.2), Sexual Masochism (302.83), sexual Sadism (302.84), Transvestic Fetishism (302.3), Voyeurism (302.82) and Paraphilia Not Otherwise Specified (302.9); gender identity disorders such as Gender Identity Disorder in Children (302.6) and Gender Identity Disorder
  • the compounds of the invention may also be of use as anticonvulsants.
  • the compounds of the invention are thus useful in the treatment of convulsions in mammals, and particularly epilepsy in humans.
  • "Epilepsy” is intended to include the following seizures: simple partial seizures, complex partial seizures, secondary generalised seizures, generalised seizures including absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic clonic seizures and atonic seizures.
  • the invention also provides a method of treating convulsions, which comprises administering to a mammal in need thereof an effective amount of a compound of the invention as hereinbefore described or a salt thereof.
  • Treatment of epilepsy may be carried out by the administration of a nontoxic anticonvulsant effective amount of a compound of the formula (I) or a salt thereof.
  • the compounds of the invention may also be of use in the treatment of neuropathic pain, for example in diabetic neuropathy, sciatica, non-specific lower back pain, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, neuralgia such as post-herpetic neuralgia and trigeminal neuralgia and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain for example in diabetic neuropathy, sciatica, non-specific lower back pain, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, neuralgia such as post-herpetic neuralgia and trigeminal neuralgia and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions.
  • treatment refers to the alleviation and/or cure of established symptoms as well as prophylaxis.
  • the invention thus provides compounds of formula (I) and pharmaceutically acceptable salts thereof for use in therapy.
  • the invention also provides compounds of formula (I) and pharmaceutically acceptable salts thereof for use in the treatment of a disorder mediated by GIyTI .
  • a method of treating a disorder mediated by GIyTI comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • a pharmaceutical composition of the invention is usually adapted for oral, sub-lingual, buccal, parenteral (for example, subcutaneous, intramuscular, or intravenous), rectal, topical and intranasal administration and in forms suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • parenteral for example, subcutaneous, intramuscular, or intravenous
  • rectal topical and intranasal administration and in forms suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • inhalation or insufflation either through the mouth or nose.
  • oral administration is provided.
  • compositions suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets, or lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions.
  • compositions suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically, a flavoured base, such as sugar and acacia or tragacanth and pastilles comprising the active compound in an inert base, such as gelatin and glycerin or sucrose and acacia.
  • a flavoured base such as sugar and acacia or tragacanth
  • pastilles comprising the active compound in an inert base, such as gelatin and glycerin or sucrose and acacia.
  • compositions suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution may be isotonic with the blood of the intended recipient. Such solutions may be administered intravenously or by subcutaneous or intramuscular injection.
  • compositions suitable for rectal administration may be provided as unit-dose suppositories comprising the active ingredient and one or more solid carriers forming the suppository base, for example, cocoa butter.
  • compositions suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils.
  • Suitable carriers for such compositions include petroleum jelly, lanolin, polyethylene glycols, alcohols, and combinations thereof.
  • compositions of the invention may be prepared by any suitable method, typically by uniformly and intimately admixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.
  • a tablet may be prepared by compressing an intimate mixture comprising a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
  • Aqueous solutions for parenteral administration are typically prepared by dissolving the active compound in sufficient water to give the desired concentration and then rendering the resulting solution sterile and isotonic.
  • the compound may be administered in single or divided doses and may be administered one or more times, for example 1 to 4 times per day.
  • a proposed dose of the active ingredient for use according to the invention for oral, sublingual, parenteral, buccal, rectal, intranasal or topical administration to a human (of approximately 70 kg bodyweight) for the treatment of neurological and neuropsychiatric disorders mediated by a GIyTI inhibitor, including schizophrenia, may be about 0.1 to about 1000 mg, for example about 0.5 mg to about 1000mg, or about 1 mg to about 1000 mg, or about 5 mg to about 500 mg, or about 10 mg to about 100 mg of the active ingredient per unit dose, which could be administered, for example, 1 to 4 times per day.
  • the compounds of formula (I) and their salts thereof may also be suitable for combination with other therapeutic agents, such as typical and atypical antipsychotics.
  • the present invention also provides:
  • a combination comprising a compound of formula (I) with one or more further therapeutic agents such an one or more antipsychotic; ii) a pharmaceutical composition comprising a combination product as defined in i) above and at least one carrier, diluent or excipient; iii) the use of a combination as defined in i) above in the manufacture of a medicament for treating or preventing a disease or condition caused by a reduction or imbalance in glutamate receptor function in a mammal; iv) a combination as defined in i) above for use in treating or preventing a disease or condition caused by a reduction or imbalance in glutamate receptor function in a mammal; v) a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising a compound of the invention and one or more further dosage forms each comprising a antipsychotic agent for simultaneous therapeutic administration, vi) a combination as defined in i) above for use in therapy; vii) a method of treatment or prevention
  • adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices.
  • This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration.
  • Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) or a salt thereof and at least one antipsychotic agent are within the scope of the current invention.
  • a patient is typically stabilised on a therapeutic administration of one or more of the of the components for a period of time and then receives administration of another component.
  • the compounds of formula (I) or a salt thereof may be administered as adjunctive therapeutic treatment to patients who are receiving administration of at least one antipsychotic agent, but the scope of the invention also includes the adjunctive therapeutic administration of at least one antipsychotic agent to patients who are receiving administration of compounds of formula (I) or a salt thereof.
  • the combination therapies of the invention may also be administered simultaneously.
  • simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously.
  • Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) or a salt thereof to a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention provides the use of compounds of formula (I) or a salt thereof in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention further provides compounds of formula (I) or a salt thereof for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one antipsychotic agent to a patient receiving therapeutic administration of compounds of formula (I) or a salt thereof.
  • the invention provides the use of at least one antipsychotic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt thereof.
  • the invention further provides at least one antipsychotic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt thereof.
  • the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) or a salt thereof in combination with at least one antipsychotic agent.
  • the invention further provides the use of a combination of compounds of formula (I) or a salt thereof and at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • the invention further provides the use of compounds of formula (I) or a salt thereof in the manufacture of a medicament for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder.
  • the invention further provides compounds of formula (I) or a salt thereof for use for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder.
  • the invention further provides the use of at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) or a salt thereof in the treatment of a psychotic disorder.
  • the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a pharmaceutical composition comprising compounds of formula (I) or a salt thereof and at least one mood stabilising or antimanic agent, a pharmaceutical composition comprising compounds of formula (I) or a salt thereof and at least one mood stabilising or antimanic agent, the use of a pharmaceutical composition comprising compounds of formula (I) or a salt thereof and at least one mood stabilising or antimanic agent in the manufacture of a medicament for the treatment of a psychotic disorder, and a pharmaceutical composition comprising compounds of formula (I) or a salt thereof and at least one mood stabilising or antimanic agent for use in the treatment of a psychotic disorder.
  • antipsychotic drugs examples include, but are not limited to: butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene; thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines; imidazolidinones; benziso- thiazolyl-piperazines; triazine such as lamotrigine; dibenzoxazepines, such as loxapine; dihydroindolones, such as molindone; aripiprazole
  • tradenames and suppliers of selected antipsychotic drugs are as follows: clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis); olanzapine (available under the tradename ZYPREX®, from Lilly; ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); haloperidol (available under the tradename HALDOL®, from Ortho-McNeil); chlorpromazine (available under the tradename THORAZINE®, from SmithKline Beecham (GSK); fluphenazine (available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena); thiothixene (available under the tradename
  • benperidol (Glianimon®), perazine (Taxilan®) or melperone (Eunerpan®)) may be used.
  • Other antipsychotic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRI N®), chlorprothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®;), prochlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename PIPOTRIL®), ziprasidone, and hoperidone.
  • promazine available under the tradename SPARINE®
  • triflurpromazine available under the tradename VESPRI N®
  • chlorprothixene available under the tradename TARACTAN®
  • droperidol
  • antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1 B antagonists, 5HT1 D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents, as well as cognitive enhancers.
  • antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1 B antagonists, 5HT1 D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents,
  • Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
  • Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
  • Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • Suitable anticonvulsant agents which may be used in combination of the compounds of the invention include for example divalproex, carbamazepine and diazepam.
  • the starting material may not necessarily have been prepared from the batch detailed in the relevant Description. All quoted retention times are as measured using LC/MS (Liquid Chromatography/Mass Spectrometry). Where appropriate, these retention times were used as a guide for purification using mass-directed auto-preparation (MDAP), which refers to purification by HPLC, wherein fraction collection is triggered by detection of the programmed mass ion for the compound of interest.
  • MDAP mass-directed auto-preparation
  • SCX cartridge refers to strong cationic exchange chromatography cartridges, specifically Varian Bond ElutTM MEGA BE_SCX cartridges.
  • Phase separation cartridge refers to Biotage lsolute Phase Separator.
  • NMR spectra were obtained at between 294 and 296K at 400MHz frequency using either a BrukerTM DPX400 or AV400 machine and run as a dilute solution of CDCI3 unless otherwise stated. All NMR spectra were referenced to tetramethylsilane (TMS ⁇ H 0, ⁇ c 0). All coupling constants are reported in hertz (Hz), and multiplicities are labelled s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), dt (doublet of triplets) and m (multiplet). Total ion current traces were obtained for electrospray positive and negative ionisation (ES+ / ES-) and/or atmospheric pressure chemical positive and negative ionisation (AP+ / AP-).
  • ES+ / ES- electrospray positive and negative ionisation
  • AP+ / AP-
  • UV wavelength range 220 -330 nm
  • Mass-directed HPLC refers to methods where the material was purified by HPLC wherein fraction collection is triggered by detection of the programmed mass ion for the compound of interest.
  • B Acetonitrile +0.1 % Formic acid Flow rate: 20 or 40 ml/min
  • Example 1 2-[3-(4-Bromophenyl)-2,2-dioxido-2-thia-1,3-diazaspiro[4.5]dec-1-yl]-N- [3-(trifluoromethyl)phenyl]acetamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne les composés sultam, leurs procédés de préparation, les compositions pharmaceutiques et les médicaments les contenant et leur utilisation dans le traitement des affections associées avec GlyT1, dont les maladies neurologiques et neuropsychiatriques, en particulier les psychoses, la démence ou les troubles du déficit de l’attention, de formule (I) ou leur sel, X étant -CH2 – ou oxygène. Des exemples de composés de l’invention figurent ci-après.
PCT/EP2009/059456 2008-07-25 2009-07-22 Phénylacétamides à substitution 2-thia-1,3-diazaspirocyclique utilisés comme médiateurs glt1 dans les maladies neurologiques WO2010010133A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0813694.7A GB0813694D0 (en) 2008-07-25 2008-07-25 Compounds
GB0813694.7 2008-07-25

Publications (1)

Publication Number Publication Date
WO2010010133A1 true WO2010010133A1 (fr) 2010-01-28

Family

ID=39746978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/059456 WO2010010133A1 (fr) 2008-07-25 2009-07-22 Phénylacétamides à substitution 2-thia-1,3-diazaspirocyclique utilisés comme médiateurs glt1 dans les maladies neurologiques

Country Status (2)

Country Link
GB (1) GB0813694D0 (fr)
WO (1) WO2010010133A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164520A1 (fr) 2014-04-24 2015-10-29 Dart Neuroscience, Llc Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1
US10040759B2 (en) 2014-11-05 2018-08-07 Dart Neuroscience (Cayman) Ltd. Substituted azetidinyl compounds as GlyT1 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039800A1 (fr) * 2002-11-01 2004-05-13 Merck Sharp & Dohme Limited Sulfamides cycliques inhibiteurs de la gamma-secretase
WO2008073459A1 (fr) * 2006-12-12 2008-06-19 Wyeth Dérivés d'aryl sulfamide et leurs procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039800A1 (fr) * 2002-11-01 2004-05-13 Merck Sharp & Dohme Limited Sulfamides cycliques inhibiteurs de la gamma-secretase
WO2008073459A1 (fr) * 2006-12-12 2008-06-19 Wyeth Dérivés d'aryl sulfamide et leurs procédés d'utilisation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164520A1 (fr) 2014-04-24 2015-10-29 Dart Neuroscience, Llc Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1
US9708334B2 (en) 2014-04-24 2017-07-18 Dart Neuroscience (Cayman) Ltd. Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors
US10040759B2 (en) 2014-11-05 2018-08-07 Dart Neuroscience (Cayman) Ltd. Substituted azetidinyl compounds as GlyT1 inhibitors

Also Published As

Publication number Publication date
GB0813694D0 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
US20120004273A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
US20090326027A1 (en) N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors
EP1833811B1 (fr) Hétérocycles oxygénés en tant que composés inhibiteurs de transporteurs de glycine
US20100029700A1 (en) 1-(2-aryl-2-oxoethyl)-3-phenyl-1, 4-diazaspiro [4.5]dec-3-en-2-one derivatives and their use as glycine transporter inhibitors
US20090062360A1 (en) Compounds Which Inhibit the Glycine Transporter and Uses Thereof
EP1874721A2 (fr) Inhibiteurs du transport de la glycine
EP1838663A1 (fr) Inhibiteurs du transport de la glycine
US20090325993A1 (en) GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
WO2009034062A1 (fr) Composés qui inhibent le transporteur de glycine et ses utilisations en médecine
US20100113545A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2010010133A1 (fr) Phénylacétamides à substitution 2-thia-1,3-diazaspirocyclique utilisés comme médiateurs glt1 dans les maladies neurologiques
US20100048656A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
US20100105713A1 (en) GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
US20090227629A1 (en) Compounds having activity at the glycine transporter glyt1 and uses thereof
US20100016374A1 (en) Compounds Which Inhibit the Glycine Transporter and Uses Thereof
US20100016399A1 (en) GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
WO2007147836A1 (fr) Composés inhibant le transporteur de la glycine et utilisations en médecine
WO2007147839A1 (fr) Composés inhibant le transporteur de la glycine et utilisations de ceux-ci en médecine
US20100317704A1 (en) Spiro-condensed imidazolone derivatives inhibiting the glycine transporter
US20110009440A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09780953

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 11.04.11 AND 01.08.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09780953

Country of ref document: EP

Kind code of ref document: A1